Repligen Corporation (NASDAQ:RGEN – Get Free Report) shares passed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $177.82 and traded as high as $181.56. Repligen shares last traded at $178.27, with a volume of 1,019,567 shares traded.
Analyst Ratings Changes
A number of equities analysts recently issued reports on RGEN shares. Weiss Ratings cut shares of Repligen from a “hold (c)” rating to a “sell (d+)” rating in a research note on Monday. UBS Group restated a “buy” rating on shares of Repligen in a research note on Tuesday, September 29th. Citigroup raised shares of Repligen to a “buy” rating in a report on Tuesday, July 7th. JPMorgan Chase & Co. lifted their target price on shares of Repligen from $165.00 to $175.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Finally, Benchmark upgraded shares of Repligen from a “hold” rating to a “buy” rating and set a $185.00 target price on the stock in a research note on Tuesday, July 7th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $178.57.
Read Our Latest Report on RGEN
Repligen Trading Up 3.1%
The stock has a fifty day simple moving average of $177.82 and a 200 day simple moving average of $145.34. The company has a debt-to-equity ratio of 0.27, a quick ratio of 8.43 and a current ratio of 9.88. The firm has a market cap of $11.40 billion, a P/E ratio of -848.86, a price-to-earnings-growth ratio of 2.96 and a beta of 1.11.
Repligen (NASDAQ:RGEN – Get Free Report) last announced its quarterly earnings results on Tuesday, October 27th. The biotechnology company reported $0.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.07. Repligen had a positive return on equity of 5.49% and a negative net margin of 1.47%. The firm had revenue of $209.31 million for the quarter, compared to the consensus estimate of $206.70 million. During the same period in the prior year, the company posted $0.46 earnings per share. The company’s quarterly revenue was up 10.9% on a year-over-year basis. On average, research analysts expect that Repligen Corporation will post 2.07 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Repligen
Several hedge funds and other institutional investors have recently bought and sold shares of RGEN. Ethic Inc. bought a new position in Repligen in the third quarter valued at about $587,000. Heritage Family Offices LLP purchased a new position in Repligen in the third quarter worth about $80,000. Kestra Advisory Services LLC bought a new stake in shares of Repligen during the 3rd quarter valued at about $360,000. Associated Banc Corp bought a new stake in shares of Repligen during the 3rd quarter valued at about $226,000. Finally, Integrity Alliance LLC. bought a new position in shares of Repligen in the 3rd quarter worth approximately $306,000. Institutional investors own 97.64% of the company’s stock.
Repligen Company Profile
Repligen Corporation (NASDAQ:RGEN) develops and manufactures bioprocessing technologies used in the production of biological medicines. Its products support key stages of biopharmaceutical manufacturing, including upstream processing, downstream purification, filtration, process monitoring and fluid management.
The company’s offerings include chromatography products, filtration systems, single-use technologies, process analytics equipment and critical biological materials such as recombinant proteins.
Featured Articles
- Five stocks we like better than Repligen
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.
